Oxaliplatin enters tumor cells via copper transporter 1 (CTR1), where it goes through the activation step of chlorine ligand substitution, usually replaced by water molecules or other small molecules containing sulfhydryl groups. This evidence concerns the gene SLC31A1 and neoplasm.